MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib

Схожие документы

• Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report
  по: Go Makimoto, et al.
  Опубликовано: (2022-05-01)
• Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer
  по: Ichihara, Eiki, et al.
  Опубликовано: (2018)
• Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression
  по: Nishii, Kazuya, et al.
  Опубликовано: (2021)
• VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers
  по: Watanabe, Hiromi, et al.
  Опубликовано: (2021)
• Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS1 fusions
  по: Kato, Yuka, et al.
  Опубликовано: (2018)